Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | TDO2 | P48775 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588409 | 1.00 | IDO1 (0.59) | IDO1TDO2ADRB2SCN4ADPP4 | |
| SCHEMBL587761 | 1.00 | IDO1 (0.59) | IDO1TDO2ADRB2SCN4ADPP4 | |
| Hydrochloric Acid SCHEMBL1143208 | 0.98 | IDO1 (0.61) | IDO1TDO2ADRB2SCN4ADPP4 | |
| Hydrochloric Acid SCHEMBL3998446 | 0.95 | IDO1 (0.55) | IDO1TDO2ADRB2SCN4ADPP4 | |
| SCHEMBL1732927 | 0.89 | ADRB2 (0.62) | IDO1TDO2ADRB2TSHRHIF1A | |
| Hydrochloric Acid SCHEMBL3179658 | 0.87 | ADRB2 (0.59) | IDO1TDO2ADRB2TSHRHIF1A | |
| SCHEMBL11480062 | 0.87 | DPP4 (0.61) | DPP4F2TSHRHIF1AADRA2A | |
| SCHEMBL11478580 | 0.87 | DPP4 (0.61) | DPP4F2TSHRHIF1AADRA2A | |
| Aminodiphenylmethane SCHEMBL7841 | 0.84 | DPP4 (0.65) | DPP4F2TSHRHIF1AADRA2A | |
| Aminodiphenylmethane SCHEMBL7719817 | 0.81 | DPP4 (0.55) | DPP4F2TSHRHIF1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | claimed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | claimed |
| CN-101356162-A | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-01-28 | — | — | CN | claimed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | claimed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | claimed |
| EP-3548034-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | Microbiotix, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-2429530-B1 | (S)-MECLIZINE FOR TREATING ISCHAEMIA-REPERFUSION INJURY | MASSACHUSETTS GEN HOSPITAL (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2018106667-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-9399032-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CIPLA LIMITED (IN) | 2011-07-28 | — | — | US | disclosed |
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | disclosed |
| WO-2010132821-A2 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | disclosed |
| WO-2009057133-A2 | A PROCESS FOR THE SYNTHESIS OF 2-[2-[4-[(4-CHLOROPHENYL)PHENYL METHYL]-1-PIPERAZINYL] ETHOXY ACETIC ACID | GLENMARK GENERICS LIMITED (IN) | 2009-05-07 | — | — | WO | disclosed |
| CN-101356162-A | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-01-28 | — | — | CN | disclosed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CYP3A5, CYP4A11, IL5 | IDO1 296/4885TDO2 513/4885ADRB2 91/4885 |
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | PINK1, PC, PCK2 | IDO1 1083/4885TDO2 2057/4885ADRB2 1359/4885 |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | PINK1, PC, PCK2 | IDO1 1083/4885TDO2 2057/4885ADRB2 1359/4885 |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | HRH4, HRH1, HRH2 | IDO1 400/4885TDO2 710/4885ADRB2 457/4885 |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | PINK1, PC, PCK2 | IDO1 1083/4885TDO2 2057/4885ADRB2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.